From first click to promising trials in minutes
Enter the patient's cancer details below – including specifics like molecular profile and prior treatments – and HealthScout will rapidly:
- Identify trials precisely matching their condition
- Present a custom summary and analysis about each trial and its drugs, empowering you to find the best fit
Note: HealthScout is in early release and currently includes trials for advanced/metastatic non-small cell lung cancer, and site-agnostic advanced/metastatic solid tumor trials. We are planning to add more cancer types soon! Click here to sign up for updates.
How It Works
1/Our AI translates the patient's info into a computer-readable format
"...had progression on carbo/taxol/Keytruda..."
- Had treatment regimen of:
- Carboplatin (drug class: cytotoxic chemotherapy)
- Paclitaxel (drug class: cytotoxic chemotherapy)
- Pembrolizumab (drug class: PD-1/PD-L1 inhibitor)
- Result of regimen: progression
2/This data is used to get a list of matching trials
Trial inclusion criterion:
Progression on regimen containing chemotherapy and PD-1/PD-L1 inhibitor
- Regimen must contain:
- ≥1 drug in class: cytotoxic chemotherapy
- ≥1 drug in class: PD-1/PD-L1 inhibitor
- Result of regimen must have been: progression
3/Learn about the matching trials and find the ones that are the best fit
Tags in the trials list help you zero in on the best trials. Trials with better tags show up first.
The Trial Details page shows matching cohorts and eligibility criteria:
Cohorts: The patient is potentially eligible for Cohort B (NSCLC with EGFR mutation).
✓Inclusion: Progression on regimen containing chemotherapy and PD-1/PD-L1 inhibitor
✓Inclusion: Has EGFR mutation
?Exclusion: Known active tuberculosis
Our analysis helps identify the most promising drugs and trials:
Zongertinib clinical results
Zongertinib has shown promising preliminary results in ongoing clinical trials. In the Beamion LUNG-1 trial (NCT04886804), a Phase Ia/Ib first-in-human study, zongertinib demonstrated high response rates, particularly among NSCLC patients.
The drug was well tolerated, with low rates of EGFR-mediated adverse events and no discontinuations due to adverse events recorded during the Phase Ib trial. Initial efficacy data from Phase Ib reflected a high objective response rate (ORR) of 74% and a disease control rate (DCR) of 91% [1].
[1] Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor, in patients with HER2-positive advanced NSCLC.
About Us
Who created HealthScout?
The HealthScout team is led by Michael Gensheimer MD, a radiation oncologist at Stanford University. Dr. Gensheimer noticed that many of his patients were interested in clinical trials but were struggling to find ones that were a good fit. This inspired him to create HealthScout. He has been a faculty member at Stanford since 2015 and his deep involvement in clinical trials includes serving as an investigator for phase 1 studies, leading investigator-initiated phase 2 trials, and enrolling patients on large phase 3 trials.
Is the site secure?
Yes, user data is encrypted at all times and HealthScout lives on the secure Render.com platform. Also, you never need to enter any personal information like date of birth. We do ask for a name for each patient, but you can just use their initials or first name.
Is HealthScout free to use?
Yes it is. HealthScout is non-commercial and we do not sell user data to any third parties.
